| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:30Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-14T07:10:40Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 國立成功大學 |
2022 |
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
Wang, M.;Yang, J.C.-H.;Mitchell, P.L.;Fang, J.;Camidge, D.R.;Nian, W.;Chiu, Chiu C.-H.;Zhou, J.;Zhao, Y.;Su, W.-C.;Yang, T.-Y.;Zhu, V.W.;Millward, Millward M.;Fan, Y.;Huang, W.-T.;Cheng, Y.;Jiang, L.;Brungs, D.;Bazhenova, L.;Lee, C.K.;Gao, B.;Xu, Y.;Hsu, W.-H.;Zheng, L.;J�nne, P.A. |
| 國立成功大學 |
2022 |
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
|
Wu, Y.-L.;Lu, S.;Yang, J.C.-H.;Zhou, J.;Seto, T.;Ahn, M.-J.;Su, W.-C.;Yamamoto, N.;Kim, D.-W.;Paolini, J.;Usari, T.;Iadeluca, L.;Wilner, K.D.;Goto, K. |
| 國立成功大學 |
2022 |
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor– Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
|
J�nne, P.A.;Baik, C.;Su, W.-C.;Johnson, M.L.;Hayashi, Hayashi H.;Nishio, M.;Kim, D.-W.;Koczywas, M.;Gold, K.A.;Steuer, C.E.;Murakami, H.;Yang, J.C.-H.;Kim, S.-W.;Vigliotti, M.;Shi, R.;Qi, Z.;Qiu, Y.;Zhao, L.;Sternberg, D.;Yu, C.;Yu, H.A. |
| 臺大學術典藏 |
2021-11-03T05:24:55Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; CHONG-JEN YU; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-11-03T02:33:02Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; JIN-YUAN SHIH; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-11-03T02:33:00Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; Yang J.C.-H.; JIN-YUAN SHIH; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2021-10-27T03:22:22Z |
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients �V A Taiwanese study
|
Wu T.-H.; Lee L.J.-H.; CHANG-TSU YUAN; Chen T.W.-W.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-10-04T07:15:39Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T05:41:27Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; KAI-LUN YU; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2021-09-17T03:21:17Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
SHENG-KAI LIANG; Ko J.-C.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-09T05:25:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-09T05:25:27Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-01T01:53:45Z |
Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas
|
Wu P.-F.; Huang W.-C.; Yang J.C.-H.; Lu Y.-S.; Shih J.-Y.; Wu S.-G.; Lin C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:41Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S.; Lin C.-C.; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; Yang J.C.-H.; ANN-LII CHENG; Ghalib M.H.; Chuadhary I.; Goel S. |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:20Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Liao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; ANN-LII CHENG; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:49Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; ANN-LII CHENG; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:47Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Lin Z.-Z.; Lan K.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:45Z |
Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice
|
Liang Y.-H.; Shao Y.-Y.; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; ANN-LII CHENG; Lai M.-S. |
